{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:25:28Z","timestamp":1793787928603,"version":"4.6.1"},"reference-count":158,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jaci.2026.08.023","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:22:07Z","timestamp":1788823327000},"page":"1192-1203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pumping the brakes: Immune checkpoints as regulators of immunity and targets of cancer therapy"],"prefix":"10.1016","volume":"158","author":[{"given":"Musaab A.","family":"Alhezam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey A.","family":"Rimland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5779-4193","authenticated-orcid":false,"given":"Pui Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.08.023_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adf2947","article-title":"Immune checkpoint therapy: forging ahead","volume":"14","author":"Sharma","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2026.08.023_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/ctd2.70001","article-title":"Challenges and advances of immune checkpoint therapy","volume":"4","author":"Li","year":"2024","journal-title":"Clinical and Translational Discovery"},{"key":"10.1016\/j.jaci.2026.08.023_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009063","article-title":"Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision","volume":"12","author":"Emens","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaci.2026.08.023_bib4","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jaci.2026.08.023_bib5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.08.023_bib6","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O'Day","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaci.2026.08.023_bib7","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaci.2026.08.023_bib8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.08.023_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.08.023_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/d41573-025-00001-5","article-title":"2024 FDA approvals","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2026.08.023_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2026.08.023_bib12","article-title":"Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy","volume":"14","author":"Su","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaci.2026.08.023_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.08.023_bib14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s43018-024-00730-3","article-title":"Clinical and translational attributes of immune-related adverse events","volume":"5","author":"Suijkerbuijk","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jaci.2026.08.023_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jaci.2026.08.023_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaci.2026.08.023_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1391724","article-title":"Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis","volume":"14","author":"Shen","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.jaci.2026.08.023_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2668","article-title":"Late-onset immune-related adverse events after immune checkpoint inhibitor therapy","volume":"8","author":"Durbin","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaci.2026.08.023_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update","volume":"12","author":"Fletcher","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaci.2026.08.023_bib20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5415\/apallergy.0000000000000128","article-title":"Immunological mechanisms of tolerance: Central, peripheral and the role of T and B cells","volume":"13","author":"Meng","year":"2023","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.jaci.2026.08.023_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.70196","article-title":"Immune checkpoint molecules: a review on pathways and immunotherapy implications","volume":"13","author":"Rezazadeh-Gavgani","year":"2025","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.jaci.2026.08.023_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216758","article-title":"Unleashing the power of immune checkpoints: post-translational modification of novel molecules and clinical applications","volume":"588","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jaci.2026.08.023_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jaci.2026.08.023_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.08.023_bib26","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.ccell.2024.08.007","article-title":"Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8(+) T cells","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jaci.2026.08.023_bib27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s40425-018-0428-5","article-title":"Neoadjuvant ipilimumab (3 mg\/kg or 10 mg\/kg) and high dose IFN-alpha2b in locally\/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire","volume":"6","author":"Tarhini","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaci.2026.08.023_bib28","doi-asserted-by":"crossref","first-page":"14987","DOI":"10.1073\/pnas.0806075105","article-title":"CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients","volume":"105","author":"Liakou","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2026.08.023_bib29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/2326-6066.CIR-13-0020","article-title":"Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy","volume":"1","author":"Ng Tang","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jaci.2026.08.023_bib30","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2026.08.023_bib32","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41590-024-02027-0","article-title":"Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1(+)CD8(+) T cells","volume":"26","author":"Zhang","year":"2025","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib33","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2016-04-712612","article-title":"CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency","volume":"128","author":"Lo","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.08.023_bib34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/cei.13600","article-title":"Comprehensive comparison between 222 CTLA-4 haploinsufficiency and 212 LRBA deficiency patients: a systematic review","volume":"205","author":"Jamee","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib35","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.aaa1663","article-title":"AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy","volume":"349","author":"Lo","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jaci.2026.08.023_bib36","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bj.2021.04.005","article-title":"Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes","volume":"44","author":"Gamez-Diaz","year":"2021","journal-title":"Biomed J"},{"key":"10.1016\/j.jaci.2026.08.023_bib37","article-title":"Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1","volume":"12","author":"Hao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2017.07.014","article-title":"Lessons from CTLA-4 deficiency and checkpoint inhibition","volume":"49","author":"Lo","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib39","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2026.08.023_bib40","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1172\/JCI99036","article-title":"B cells as biomarkers: predicting immune checkpoint therapy adverse events","volume":"128","author":"Liudahl","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2026.08.023_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12060888","article-title":"CD21(lo) B cells could be a potential predictor of immune-related adverse events in renal cell carcinoma","volume":"12","author":"Nishimura","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.jaci.2026.08.023_bib42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Di Dalmazi","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.jaci.2026.08.023_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2026.08.023_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101668","article-title":"Immune checkpoint inhibitor-related hypophysitis","volume":"36","author":"Mizukoshi","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.jaci.2026.08.023_bib45","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.2217\/fon-2019-0101","article-title":"Cancer immunotherapy-associated hypophysitis","volume":"15","author":"Castillero","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.jaci.2026.08.023_bib46","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib48","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaci.2026.08.023_bib49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib50","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2026.08.023_bib51","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib52","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/s41591-021-01388-5","article-title":"Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child","volume":"27","author":"Ogishi","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2026.08.023_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019864","article-title":"T cells from Programmed death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection","volume":"6","author":"Tousif","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2026.08.023_bib54","article-title":"Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency","volume":"221","author":"Johnson","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2026.08.023_bib55","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jaci.2026.08.023_bib56","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/imr.13427","article-title":"Fc effector function of immune checkpoint blocking antibodies in oncology","volume":"328","author":"Martineau","year":"2024","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2026.08.023_bib57","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10875-025-01929-4","article-title":"The targets of immune adverse events in cancer immunotherapy by combined check-point inhibitors resemble those seen in IPEX patients","volume":"45","author":"Moraes-Fontes","year":"2025","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011652","article-title":"Therapeutic potential of targeting LAG-3 in cancer","volume":"13","author":"Davar","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaci.2026.08.023_bib59","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib60","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200239","article-title":"Overall survival and response with nivolumab and relatlimab in advanced melanoma","volume":"2","author":"Long","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jaci.2026.08.023_bib61","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1200\/JCO.24.01124","article-title":"Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047","volume":"43","author":"Tawbi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2026.08.023_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1267743","article-title":"CD4 and LAG-3 from sharks to humans: related molecules with motifs for opposing functions","volume":"14","author":"Takizawa","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib63","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1084\/jem.20100466","article-title":"PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice","volume":"208","author":"Okazaki","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2026.08.023_bib64","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12026-014-8524-1","article-title":"Regulation of T cell responses by the receptor molecule Tim-3","volume":"59","author":"Gorman","year":"2014","journal-title":"Immunol Res"},{"key":"10.1016\/j.jaci.2026.08.023_bib65","doi-asserted-by":"crossref","first-page":"89","DOI":"10.36401\/JIPO-23-4","article-title":"T cell immunoglobulin and mucin domain containing protein 3 (TIM-3) inhibitors in oncology clinical trials: a review","volume":"7","author":"Duong","year":"2024","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.jaci.2026.08.023_bib66","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","article-title":"TIM-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"595","author":"Dixon","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2026.08.023_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.adk4594","article-title":"TIM3 is a context-dependent coregulator of cytotoxic T cell function","volume":"18","author":"Alamir","year":"2025","journal-title":"Sci Signal"},{"key":"10.1016\/j.jaci.2026.08.023_bib68","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41588-018-0289-3","article-title":"Human disease mutations highlight the inhibitory function of TIM-3","volume":"50","author":"Dixon","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2026.08.023_bib69","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41588-018-0251-4","article-title":"Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome","volume":"50","author":"Gayden","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2026.08.023_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1271324","article-title":"Case Report: HAVCR2 mutation-associated hemophagocytic lymphohistiocytosis","volume":"14","author":"Song","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071440","article-title":"Immune-related adverse events due to cancer immunotherapy: immune mechanisms and clinical manifestations","volume":"16","author":"Casagrande","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaci.2026.08.023_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020340","article-title":"Incidence of cutaneous immune-related adverse events and outcomes in immune checkpoint inhibitor-containing regimens: a systematic review and meta-analysis","volume":"16","author":"Curkovic","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaci.2026.08.023_bib73","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.08.023_bib74","article-title":"Dermatologic toxicities related to cancer immunotherapy","volume":"14","author":"Vaez-Gharamaleki","year":"2025","journal-title":"Toxicol Rep"},{"key":"10.1016\/j.jaci.2026.08.023_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib76","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaci.2026.08.023_bib77","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1158\/1078-0432.CCR-23-3431","article-title":"Immunologic profiling of immune-related cutaneous adverse events with checkpoint inhibitors reveals polarized actionable pathways","volume":"30","author":"Lacouture","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaci.2026.08.023_bib78","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/2326-6066.CIR-22-0362","article-title":"Checkpoint blockade-induced dermatitis and colitis are dominated by tissue-resident memory T cells and Th1\/Tc1 cytokines","volume":"10","author":"Reschke","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jaci.2026.08.023_bib79","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management","volume":"23","author":"Lopez","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jaci.2026.08.023_bib80","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1111\/jdv.14143","article-title":"Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor","volume":"31","author":"Kwon","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2026.08.023_bib81","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/ijd.13970","article-title":"Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid","volume":"57","author":"Ridpath","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2026.08.023_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevImmunol.2023046895","article-title":"Cutaneous immune-related adverse events secondary to immune checkpoint inhibitors and their management","volume":"42","author":"Pach","year":"2022","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib83","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaci.2022.11.015","article-title":"Dermatologic immune-related adverse events to checkpoint inhibitors in cancer","volume":"151","author":"Shah","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11051496","article-title":"Checkpoint inhibitor-induced colitis: an update","volume":"11","author":"Losurdo","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaci.2026.08.023_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102440","article-title":"Immune checkpoint Inhibitor-Induced diarrhea and colitis: incidence and management. A systematic review and meta-analysis","volume":"109","author":"Nielsen","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jaci.2026.08.023_bib86","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008628","article-title":"Dysregulation of CD4(+) and CD8(+) resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis","volume":"12","author":"He","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaci.2026.08.023_bib87","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00428-021-03170-x","article-title":"Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis","volume":"479","author":"Hone Lopez","year":"2021","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jaci.2026.08.023_bib88","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","article-title":"Interferon-gamma-producing CD8(+) tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis","volume":"161","author":"Sasson","year":"2021","journal-title":"gastroenterology"},{"key":"10.1016\/j.jaci.2026.08.023_bib89","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-024-02895-x","article-title":"Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis","volume":"30","author":"Thomas","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2026.08.023_bib90","doi-asserted-by":"crossref","first-page":"770","DOI":"10.37349\/ei.2024.00171","article-title":"The growing potential of tofacitinib in immune checkpoint inhibitor-induced colitis: identifying remaining puzzle pieces","volume":"4","author":"Pellegrino","year":"2024","journal-title":"Exploration of Immunology"},{"key":"10.1016\/j.jaci.2026.08.023_bib91","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.trecan.2025.07.005","article-title":"Clinical perspective and treatment of immune-related colitis after cancer immunotherapy","volume":"11","author":"Braun","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jaci.2026.08.023_bib92","first-page":"358","article-title":"Diagnosis and management of immune checkpoint inhibitor colitis","volume":"17","author":"Hashash","year":"2021","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.jaci.2026.08.023_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.800879","article-title":"Immune checkpoint inhibitor-associated colitis: from mechanism to management","volume":"12","author":"Tang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib94","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4103\/ijem.ijem_47_25","article-title":"Endocrine adverse events of immune checkpoint inhibitors: a comprehensive review","volume":"29","author":"Rajan","year":"2025","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.jaci.2026.08.023_bib95","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3803\/EnM.2023.1785","article-title":"Incidence of endocrine-related dysfunction in patients treated with new immune checkpoint inhibitors: a meta-analysis and comprehensive review","volume":"38","author":"Yoo","year":"2023","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.jaci.2026.08.023_bib96","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.eprac.2025.06.008","article-title":"Risk of pituitary immune-related adverse events caused by immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"31","author":"Li","year":"2025","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jaci.2026.08.023_bib97","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2337\/dc22-2202","article-title":"Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaci.2026.08.023_bib98","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg0675","article-title":"Clonally expanded, thyrotoxic effector CD8(+) T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis","volume":"15","author":"Lechner","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2026.08.023_bib99","article-title":"Polyfunctional IL-21(+) IFNG(+) T follicular helper cells contribute to checkpoint inhibitor diabetes mellitus and can be targeted by JAK inhibitor therapy","author":"Huang","year":"2024","journal-title":"bioRxiv (preprint)"},{"key":"10.1016\/j.jaci.2026.08.023_bib100","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaci.2026.08.023_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12103468","article-title":"Progress and challenges of immune checkpoint inhibitor-induced hypophysitis","volume":"12","author":"Chen","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaci.2026.08.023_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1157805","article-title":"Endocrine side effects of immune checkpoint inhibitors","volume":"14","author":"Cardona","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jaci.2026.08.023_bib103","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1210\/clinem\/dgaf347","article-title":"Multiple or single endocrine abnormalities associated with immune checkpoint inhibitors","volume":"111","author":"Kamitani","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaci.2026.08.023_bib104","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1089\/thy.2021.0685","article-title":"Optimal thyroid hormone replacement dose in immune checkpoint inhibitor-associated hypothyroidism is distinct from Hashimoto's thyroiditis","volume":"32","author":"Mosaferi","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.jaci.2026.08.023_bib105","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.jaci.2026.08.023_bib106","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaci.2026.08.023_bib107","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13098-024-01263-6","article-title":"Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: insights into immune checkpoint inhibitors induced diabetes mellitus","volume":"16","author":"Wei","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jaci.2026.08.023_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.764138","article-title":"Unravelling checkpoint inhibitor associated autoimmune diabetes: from bench to bedside","volume":"12","author":"Wu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jaci.2026.08.023_bib109","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.eprac.2020.09.016","article-title":"Immune checkpoint inhibitor-induced adrenalitis and primary adrenal insufficiency: systematic review and optimal management","volume":"27","author":"Shi","year":"2021","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jaci.2026.08.023_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","article-title":"Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database","volume":"145","author":"Sato","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jaci.2026.08.023_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/ph17040501","article-title":"Neurological adverse events related to immune checkpoint inhibitors: a practical review","volume":"17","author":"Zammit","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jaci.2026.08.023_bib112","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","article-title":"Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes","volume":"23","author":"Farina","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jaci.2026.08.023_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2025.101956","article-title":"The pathogenesis of neurological immune-related adverse events following immune checkpoint inhibitor therapy","volume":"78","author":"Lerch","year":"2025","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib114","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/jnnp-2025-335998","article-title":"Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist","volume":"96","author":"Willis","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jaci.2026.08.023_bib115","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2026.08.023_bib116","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s40425-019-0821-8","article-title":"Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study","volume":"7","author":"Manson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaci.2026.08.023_bib117","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000604","article-title":"Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors","volume":"6","author":"Vogrig","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jaci.2026.08.023_bib118","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2026.08.023_bib119","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2026.08.023_bib120","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s12967-024-05177-9","article-title":"Immune checkpoint inhibitors induce acute interstitial nephritis in mice with increased urinary MCP1 and PD-1 glomerular expression","volume":"22","author":"Martinez Valenzuela","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.jaci.2026.08.023_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2022.1017921","article-title":"Immune checkpoint inhibitor related nephrotoxicity: advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge","volume":"2","author":"Miao","year":"2022","journal-title":"Front Nephrol"},{"key":"10.1016\/j.jaci.2026.08.023_bib122","article-title":"The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity","volume":"9","author":"Moss","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaci.2026.08.023_bib123","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clim.2005.01.005","article-title":"PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis","volume":"115","author":"Ding","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib124","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1080\/0886022X.2022.2147439","article-title":"Glomerular diseases after immune checkpoint inhibitors use: what do we know so far?","volume":"44","author":"He","year":"2022","journal-title":"Ren Fail"},{"key":"10.1016\/j.jaci.2026.08.023_bib125","article-title":"Immune checkpoint inhibitors and acute kidney injury","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib126","doi-asserted-by":"crossref","first-page":"803","DOI":"10.34067\/KID.0003902021","article-title":"Is rechallenge appropriate in patients that develop immune checkpoint inhibitor-associated AKI?","volume":"3","author":"Kanduri","year":"2022","journal-title":"CON. Kidney360"},{"key":"10.1016\/j.jaci.2026.08.023_bib127","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002292","article-title":"Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study","volume":"9","author":"Lee","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaci.2026.08.023_bib128","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.resinv.2025.07.023","article-title":"Immune checkpoint inhibitor-related pneumonitis: from guidelines to the front lines","volume":"63","author":"Karayama","year":"2025","journal-title":"Respir Investig"},{"key":"10.1016\/j.jaci.2026.08.023_bib129","article-title":"Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management","volume":"15","author":"Lin","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib130","article-title":"Checkpoint inhibitor pneumonitis: key insights for pulmonologists","volume":"61","author":"Serra","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.jaci.2026.08.023_bib131","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/PAS.0000000000001298","article-title":"Clinical and histopathologic features of immune checkpoint inhibitor-related pneumonitis","volume":"43","author":"Larsen","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jaci.2026.08.023_bib132","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","volume":"47","author":"Power","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaci.2026.08.023_bib133","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2512645","article-title":"A review of immune checkpoint inhibitor-associated myocarditis: epidemiology, pathogenesis, and biomarkers","volume":"21","author":"Xu","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jaci.2026.08.023_bib134","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","article-title":"Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis","volume":"149","author":"Ma","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jaci.2026.08.023_bib135","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1002\/ehf2.15281","article-title":"Immune checkpoint inhibitors and cardiovascular adverse events","volume":"12","author":"De Perna","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jaci.2026.08.023_bib136","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.08.023_bib137","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"24","author":"Davis","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jaci.2026.08.023_bib138","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaci.2026.08.023_bib139","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaci.2026.08.023_bib140","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3892\/ol.2024.14463","article-title":"Cytokine release syndrome induced by immune checkpoint inhibitor treatment for uterine cervical cancer recurrence: a case report","volume":"28","author":"Sekimata","year":"2024","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jaci.2026.08.023_bib141","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.807050","article-title":"Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature","volume":"13","author":"Tay","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib142","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-020-04665-7","article-title":"Immune checkpoint inhibitor-induced musculoskeletal manifestations","volume":"41","author":"Angelopoulou","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jaci.2026.08.023_bib143","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41467-022-29539-3","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.08.023_bib144","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add1591","article-title":"Clonally expanded CD38(hi) cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis","volume":"8","author":"Wang","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2026.08.023_bib146","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaci.2026.08.023_bib147","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaci.2026.08.023_bib148","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines(R) insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jaci.2026.08.023_bib149","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.it.2024.11.014","article-title":"Targeting molecular pathways to control immune checkpoint inhibitor toxicities","volume":"46","author":"Reschke","year":"2025","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jaci.2026.08.023_bib150","first-page":"912","article-title":"Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"33","author":"Cruz Carreras","year":"2025","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaci.2026.08.023_bib151","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001287","article-title":"Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab","volume":"8","author":"Lin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaci.2026.08.023_bib152","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1212\/WNL.0000000000205416","article-title":"A successful treatment story of a patient with immune checkpoint inhibitor associated myositis and myasthenia gravis (P4-14.012)","volume":"102","author":"Yu","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.jaci.2026.08.023_bib153","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3892\/etm.2025.12947","article-title":"Efgartigimod for immune checkpoint inhibitor induced polyradiculoneuropathy and cardiomyopathy: a case report","volume":"30","author":"Dong","year":"2025","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jaci.2026.08.023_bib154","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/cancers12030546","article-title":"Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaci.2026.08.023_bib155","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.40695","article-title":"Survival among veterans receiving steroids for immune-related adverse events after immune checkpoint inhibitor therapy","volume":"6","author":"Van Buren","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaci.2026.08.023_bib156","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41698-023-00380-1","article-title":"Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance","volume":"7","author":"Verheijden","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jaci.2026.08.023_bib157","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16101892","article-title":"Studying outcomes after steroid-sparing immunosuppressive agent vs. steroid-only treatment for immune-related adverse events in non-small-cell lung cancer (NSCLC) and melanoma: a retrospective case-control study","volume":"16","author":"Syed","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaci.2026.08.023_bib158","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926006329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926006329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:35:35Z","timestamp":1793784935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926006329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":158,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0091674926006329"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.08.023","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pumping the brakes: Immune checkpoints as regulators of immunity and targets of cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}